speaker-icon

Latest Posts

anavex_partex_partnership_Innoplexus

27

Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More
Kittu-Press-Release

9

Feb 23

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros

The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

Author name: Lawrence Ganti

Lawrence Ganti is the Global President of Life Sciences, CEO of  Americas, and Member of the Global Executive Community. Prior to joining Innoplexus, Lawrence spent 15 years leading teams across functions and geographies in the pharmaceutical industry. He also worked as a research associate for McKinsey & Company and holds an MBA from IMD in Switzerland and a bachelors from Babson College in the United States.

Drug-Discovery

Leveraging AI for Drug Discovery in early stage Biotech Companies

Many biotech firms lack the basic data infrastructure to properly exploit digital tools and AI-technologies like machine learning, computer vision, entity normalization, network analysis, etc, and they don’t employ their own data scientists. However, some investors are specifically looking at biotech companies combining the DNA of both pharmaceutical and digital technology groups. Funding is only …

Leveraging AI for Drug Discovery in early stage Biotech Companies Read More »

artificial-intelligence

To unlock innovation, pharma needs to be honest about failure

Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock innovation – and it’s a lesson the pharmaceutical industry would do well to learn. Take Jeff Bezos, for example. As the CEO of Amazon, he encourages designing bold experiments that may lead to failure. After Amazon acquired Whole Foods, …

To unlock innovation, pharma needs to be honest about failure Read More »

why-data-analytics

Why data analytics should be Pharma’s new core competency

Defining your company’s core competency—what you do really well—can set you apart and secure a trajectory of success. Pharma’s core competency has evolved over the years. Initially, it was research and companies that were fortunate enough to discover major blockbuster drugs enjoyed profitable periods of market exclusivity. However, once the pharma market consolidated into large …

Why data analytics should be Pharma’s new core competency Read More »

machine-learning

Why machines need to speak the language of Life Sciences

Do you remember the days when NLP, known as Neuro-Linguistic Programming was all the rage in self-help books and motivational speaking? You remember the self-help gurus preaching the use of Neuro-Linguistic Programming as a method to help you achieve near superpowers to attain your goals by “modelling” the skills of so-called exceptional people. Well, since …

Why machines need to speak the language of Life Sciences Read More »